Advertisement

Mononitrate II pp 238-241 | Cite as

Comparison of the Efficacy and Acceptability of Isosorbide 5-Mononitrate, Isosorbide Dinitrate and Propranolol in the Management of Angina Pectoris

  • N. A. Irvine
  • D. Maclean
  • D. G. McDevitt
Part of the International Boehringer Mannheim Symposia book series (BOEHRINGER)

Abstract

Although isosorbide 5-mononitrate (IS-5-MN) has theoretical advantages over isosorbide dinitrate (ISDN) in terms of metabolism and bioavailability [1–3] there is no conclusive evidence to show that these are reflected in improved therapeutic benefit in clinical practice. A study has therefore been undertaken to compare the efficacy and acceptability of IS-5-MN, ISDN and the beta-adrenoreceptor antagonist propranolol (PROP) in the management of 20 patients with angina pectoris. This is an interim report.

Keywords

Angina Pectoris Intermittent Claudication Interim Report Isosorbide Dinitrate Anginal Attack 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Down WH, Chassaud LF, Grundy RK (1974) Biotransformation of isosorbide dinitrate in humans. J Pharm Sci 63: 1147–1149PubMedCrossRefGoogle Scholar
  2. 2.
    Abshagen U, Sporl-Radnn S (1980) Pharmacokinetics and effect of 5-isosorbide mononitrate (5IS-5-MN) in normal man. In: World conference on clinical pharmacology and therapeutics. MacMillan, London, p.0377Google Scholar
  3. 3.
    Abshagen U, Betzien G, Endele R, Kaufmann B (1981) Pharmacokinetics of intravenous and oral isosorbine-5-mononitrate. Eur J Clin Pharmacol 20: 269–275PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • N. A. Irvine
  • D. Maclean
  • D. G. McDevitt

There are no affiliations available

Personalised recommendations